Lexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Lexicon Pharmaceuticals is expected to release its Q2 2025 earnings on August 6th, projecting a loss of ($0.07) per share and revenue of $4.87 million.
• Analysts have mixed ratings on Lexicon Pharmaceuticals, with one sell rating, three holds, and two buys, and an average target price of $3.67.
• Institutional investors and hedge funds currently own 74.70% of Lexicon Pharmaceuticals' stock, reflecting growing interest from major financial entities.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.07) per share and revenue of $4.87 million for the quarter.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $1.26 million for the quarter, compared to analysts' expectations of $1.26 million. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX remained flat at $1.07 during mid-day trading on Friday. The stock had a trading volume of 1,138,739 shares, compared to its average volume of 3,485,551. The stock has a market cap of $386.79 million, a P/E ratio of -2.10 and a beta of 1.17. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.48. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.18. The business's fifty day moving average price is $0.90 and its 200-day moving average price is $0.70.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Lexicon Pharmaceuticals by 27.4% during the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock worth $101,000 after purchasing an additional 29,319 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Lexicon Pharmaceuticals by 173.5% during the first quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company's stock worth $132,000 after buying an additional 181,265 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter worth about $263,000. Finally, AQR Capital Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter worth about $541,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on LXRX shares. Wall Street Zen started coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a "sell" rating on the stock. HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, June 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $3.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.